Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
precisionmedicineonline2 天
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Managed Healthcare Executive2 天
CMS Cell and Gene Therapy Access Plan Earns Reprieve After Trump Halt
President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical ...
Shares of Charter Communications, Inc. CHTR +5.52% Get Free Report rose during Friday's session after the company reported ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
STAT2 天
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
BMO将Vertex股票目标价从520美元上调至545美元
周五，BMO Capital Markets上调了Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )的股票目标价，从520美元提高到545美元，同时维持"优于大市"评级。根据 InvestingPro 数据，该股目前交易价为452.73美元，低于分析师330美元至591美元的目标区间。此次调整是在Suzetrigine（现品牌名为Journavx ...
Cantor Fitzgerald维持Vertex股票"增持"评级，目标价480美元
周五，Cantor Fitzgerald重申了对Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )的"增持"评级和480.00美元的目标价。该公司目前交易价格为438.40美元，市值为1129亿美元。该公司分析师Olivia Brayer讨论了公司最近在其治疗方法上获得广泛标签的成就，引发了对潜在定价策略的疑问。根据 InvestingPro ...